STOPP Act Stop the Opioid Pill Presser and Fentanyl Act
Impact
The STOPP Act imposes requirements such as mandatory registration for manufacturers and distributors of tableting and encapsulating machines, which significantly increase regulatory oversight aimed at curbing drug production. The Attorney General is granted authority to define the registration process, including establishing a National Pill Press Registry which would track all relevant machines and parts. This heightened scrutiny of machinery used in drug production represents a fundamental shift toward more stringent regulation within the framework of the Controlled Substances Act, thereby enhancing public health safety protocols.
Summary
House Bill 1100, also known as the Stop the Opioid Pill Presser and Fentanyl Act (STOPP Act), aims to amend the Controlled Substances Act to include stringent regulations concerning the manufacture and distribution of critical parts associated with tableting and encapsulating machines. The bill responds to the growing concerns regarding opioid misuse and the proliferation of illicitly manufactured drugs, by enhancing the guidelines governing these machines and related components, thereby aiming to prevent their use in producing controlled substances illegally.
Contention
Despite broad support for the overarching goals of the STOPP Act, there are notable concerns surrounding the potential implications for legitimate manufacturers who rely on tableting and encapsulating machines. Industry stakeholders have voiced worries about the burden of compliance and the extensive regulations, fearing that such measures could stifle innovation and increase operational costs. Furthermore, the act could also disproportionately impact small manufacturers who may struggle to meet the new regulatory requirements, raising questions about the balance between enhancing public safety and maintaining industry viability.